



Sanofi Appoints Amal Makhloufi Benchouk as General Manager, General Medicines & Emerging Markets Business Unit and Philippines Country Chair

MANILA, May 21, 2018 – Sanofi announced today that effective July 1, 2018, company veteran Amal Makhloufi Benchouk has been appointed as General Manager, General Medicines & Emerging Markets Business Unit and Philippines Country Chair, replacing Carlito Realuyo who is retiring after more than 25 years of continued service and dedication to Sanofi. Amal has been with the company since 1999 and has held a number of leadership positions and most recently Chief Operating Officer for the company's affiliate in Algeria.

“We thank Carlito Realuyo for his years of service and his contributions to improve health in the Philippines, and wish him well in his retirement and future endeavors.” said Cyril Grandchamp-Desraux, Asia Head, General Medicines & Emerging Markets and Singapore Country Chair. “We are excited that Amal will assume the leadership of Sanofi in the Philippines. Her experience combined with her deep knowledge of the company positions us well to continue our efforts to improve health in the Philippines.”

Amal, a doctor by training, is a proven leader with more than 20 years of experience in sales, marketing, business intelligence and project management. She joined Sanofi in 1999 as Medical Sales Representative in Algeria, and was quickly promoted to various roles, including District Sales Manager, Product Manager, Head of Marketing, Business Development, Business Excellence and Business Unit Director. With Amal assuming her leadership role in the Philippines, Sanofi will continue its important work in the Philippines to solve the health challenges facing the people of the Philippines.

“I am honored to assume this role. Sanofi's efforts in the Philippines have led to millions of lives saved and countless more impacted for the better. For more than 50 years, the Philippines has been an important part of the Sanofi family. I'm thrilled to become a member of that family to continue our long-standing commitment to the Philippines by providing solutions to improve the health of all Filipinos,” said Amal.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life



Sanofi Forward-Looking Statements

This statement contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
